InsiderTrades.com logo

EQ Insider Trading

Insider Ownership Percentage: 30.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $540,856.15

Equillium Insider Trading History Chart

This chart shows the insider buying and selling history at Equillium by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Equillium Share Price & Price History

Current Price: $1.85
Price Change: ▲ Price Increase of +0.11 (6.32%)
As of 02/23/2026 05:00 PM ET

This chart shows the closing price history over time for EQ up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Equillium Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/19/2026Christine ZedelmayerCOOSell185,937$1.76$327,249.12191,444View SEC Filing Icon  
1/8/2026Penny TomInsiderSell6,533$1.29$8,427.57View SEC Filing Icon  
12/23/2025Christine ZedelmayerCOOSell100,000$1.50$150,000.0091,444View SEC Filing Icon  
12/15/2025Christine ZedelmayerCOOSell11,900$1.31$15,589.0091,444View SEC Filing Icon  
12/12/2025Christine ZedelmayerCOOSell23,804$1.34$31,897.36103,344View SEC Filing Icon  
11/25/2025Christine ZedelmayerCOOSell8,098$0.95$7,693.10127,148View SEC Filing Icon  
1/23/2025Jason A KeyesCFOSell10,000$0.65$6,500.0037,720View SEC Filing Icon  
11/14/2024Jason A KeyesCFOSell10,000$0.70$7,000.0047,720View SEC Filing Icon  
10/28/2024Christine ZedelmayerCOOSell15,000$1.25$18,750.00135,246View SEC Filing Icon  
10/28/2024Penny TomInsiderSell2,835$1.25$3,543.756,533View SEC Filing Icon  
10/25/2024Penny TomInsiderSell683$1.25$853.759,368View SEC Filing Icon  
9/26/2024Jason A KeyesCFOSell10,000$0.81$8,100.0057,720View SEC Filing Icon  
9/16/2024Penny TomInsiderSell38,806$0.85$32,985.1010,051View SEC Filing Icon  
7/16/2024Jason A KeyesCFOSell10,000$0.87$8,700.0067,720View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Equillium (NASDAQ:EQ)

27.05% of Equillium stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at EQ by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Equillium Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/18/2026ADAR1 Capital Management LLC5,608,078$8.69M0.6%+0.9%9.210%Search for SEC Filing on Google Icon
2/18/2026Ikarian Capital LLC303,555$0.47M0.0%-8.6%0.499%Search for SEC Filing on Google Icon
2/18/2026Janus Henderson Group PLC5,862,212$9.06M0.0%N/A9.628%Search for SEC Filing on Google Icon
2/18/2026Balyasny Asset Management L.P.2,076,250$3.22M0.0%+3.6%3.410%Search for SEC Filing on Google Icon
2/18/2026Boothbay Fund Management LLC93,211$0.14M0.0%-23.6%0.153%Search for SEC Filing on Google Icon
2/17/2026ADAR1 Capital Management LLC5,608,078$8.69M0.6%+0.9%9.210%Search for SEC Filing on Google Icon
2/17/2026Schonfeld Strategic Advisors LLC25,381$39K0.0%-79.7%0.042%Search for SEC Filing on Google Icon
2/17/2026Cantor Fitzgerald L. P.562,643$0.87M0.0%+32.4%0.924%Search for SEC Filing on Google Icon
2/17/2026Diadema Partners LP347,393$0.54M0.1%+15.8%0.571%Search for SEC Filing on Google Icon
2/17/2026Royal Bank of Canada79,734$0.12M0.0%N/A0.131%Search for SEC Filing on Google Icon
2/17/2026Persistent Asset Partners Ltd93,123$0.14M0.1%+35.0%0.153%Search for SEC Filing on Google Icon
2/13/2026Hudson Bay Capital Management LP428,538$0.66M0.0%+53.9%0.704%Search for SEC Filing on Google Icon
2/13/2026State Street Corp155,420$0.24M0.0%+13.0%0.255%Search for SEC Filing on Google Icon
2/12/2026Renaissance Technologies LLC733,226$1.14M0.0%+19.2%1.204%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC345,310$0.54M0.0%+11.1%0.567%Search for SEC Filing on Google Icon
1/16/2026Aberdeen Group plc2,366,688$3.67M0.0%+523.6%3.887%Search for SEC Filing on Google Icon
12/15/2025Hudson Bay Capital Management LP278,538$0.40M0.0%N/A0.457%Search for SEC Filing on Google Icon
12/1/2025Cantor Fitzgerald L. P.425,000$0.61M0.0%N/A0.698%Search for SEC Filing on Google Icon
11/17/2025Woodline Partners LP3,508,771$5.02M0.0%N/A5.762%Search for SEC Filing on Google Icon
11/17/2025Millennium Management LLC24,356$35K0.0%N/A0.040%Search for SEC Filing on Google Icon
11/17/2025Cantor Fitzgerald L. P.425,000$0.61M0.0%N/A0.698%Search for SEC Filing on Google Icon
11/17/2025Boothbay Fund Management LLC121,953$0.17M0.0%N/A0.200%Search for SEC Filing on Google Icon
11/14/2025Schonfeld Strategic Advisors LLC124,823$0.18M0.0%N/A0.210%Search for SEC Filing on Google Icon
11/14/2025Virtu Financial LLC23,779$34K0.0%+133.4%0.040%Search for SEC Filing on Google Icon
11/14/2025ADAR1 Capital Management LLC5,559,988$7.95M0.7%N/A9.345%Search for SEC Filing on Google Icon
11/14/2025Two Sigma Investments LP133,004$0.19M0.0%N/A0.224%Search for SEC Filing on Google Icon
11/10/2025Persistent Asset Partners Ltd68,991$99K0.1%N/A0.116%Search for SEC Filing on Google Icon
11/7/2025Vanguard Group Inc.1,313,946$1.88M0.0%+59.4%2.208%Search for SEC Filing on Google Icon
11/7/2025Aberdeen Group plc379,526$0.54M0.0%N/A0.638%Search for SEC Filing on Google Icon
2/13/2025Renaissance Technologies LLC261,400$0.20M0.0%-18.6%0.738%Search for SEC Filing on Google Icon
2/12/2025Takeda Pharmaceutical Co. Ltd.1,824,977$1.37M5.2%N/A5.151%Search for SEC Filing on Google Icon
2/11/2025DCF Advisers LLC62,947$47K0.0%+91.0%0.178%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC300,400$0.21M0.0%+43.6%0.852%Search for SEC Filing on Google Icon
5/10/2024Acadian Asset Management LLC108,691$0.25M0.0%N/A0.308%Search for SEC Filing on Google Icon
2/12/2024Decheng Capital LLC4,447,308$3.22M0.9%N/A12.663%Search for SEC Filing on Google Icon
8/9/2023DCF Advisers LLC111,623$84K0.0%-28.9%0.324%Search for SEC Filing on Google Icon
5/2/2023Victory Capital Management Inc.345,861$0.25M0.0%-89.2%1.005%Search for SEC Filing on Google Icon
2/14/2023True North Advisors LLC265,370$0.27M0.1%+50.5%0.771%Search for SEC Filing on Google Icon
2/13/2023Callan Capital LLC103,688$0.11M0.0%N/A0.301%Search for SEC Filing on Google Icon
2/9/2023Victory Capital Management Inc.3,198,745$3.52M0.0%-12.4%9.296%Search for SEC Filing on Google Icon
1/24/2023Capital CS Group LLC24,000$25K0.0%N/A0.070%Search for SEC Filing on Google Icon
11/7/2022Virtu Financial LLC24,141$54K0.0%N/A0.070%Search for SEC Filing on Google Icon
11/2/2022Victory Capital Management Inc.3,651,084$8.11M0.0%+2.1%10.651%Search for SEC Filing on Google Icon
8/11/2022DCF Advisers LLC114,027$0.23M0.1%-31.2%0.333%Search for SEC Filing on Google Icon
8/1/2022Victory Capital Management Inc.3,577,211$7.30M0.0%-0.6%10.436%Search for SEC Filing on Google Icon
5/16/2022Cota Capital Management LLC562,278$1.77M0.4%N/A1.640%Search for SEC Filing on Google Icon
5/10/2022Decheng Capital Management III Cayman LLC4,447,308$14.01M4.3%N/A12.975%Search for SEC Filing on Google Icon
5/4/2022Victory Capital Management Inc.3,597,799$11.33M0.0%+8.2%10.495%Search for SEC Filing on Google Icon
2/15/2022Samsara BioCapital LLC615,541$2.32M0.5%-16.6%2.094%Search for SEC Filing on Google Icon
2/7/2022Victory Capital Management Inc.3,325,050$12.47M0.0%+4.9%11.313%Search for SEC Filing on Google Icon
11/12/2021Geode Capital Management LLC154,185$1.05M0.0%+2.4%0.525%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Equillium logo
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Read More on Equillium

Today's Range

Now: $1.85
Low: $1.69
High: $1.85

50 Day Range

MA: $1.38
Low: $1.06
High: $1.82

52 Week Range

Now: $1.85
Low: $0.27
High: $2.35

Volume

249,853 shs

Average Volume

520,073 shs

Market Capitalization

$112.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

Who are the company insiders with the largest holdings of Equillium?

Equillium's top insider shareholders include:
  1. Christine Zedelmayer (COO)
  2. Jason A Keyes (CFO)
  3. Penny Tom (Insider)
Learn More about top insider investors at Equillium.

Who are the major institutional investors of Equillium?

Equillium's top institutional shareholders include:
  1. Janus Henderson Group PLC — 9.63%
  2. ADAR1 Capital Management LLC — 9.21%
  3. ADAR1 Capital Management LLC — 9.21%
  4. Aberdeen Group plc — 3.89%
  5. Balyasny Asset Management L.P. — 3.41%
  6. Renaissance Technologies LLC — 1.20%
Learn More about top institutional investors of Equillium stock.

Which institutional investors are selling Equillium stock?

Within the previous quarter, EQ stock was sold by these institutional investors:
  1. Schonfeld Strategic Advisors LLC
  2. Ikarian Capital LLC
  3. Boothbay Fund Management LLC
  4. Simplex Trading LLC
During the previous year, company insiders that have sold Equillium company stock include:
  1. Christine Zedelmayer (COO)
  2. Jason A Keyes (CFO)
Learn More investors selling Equillium stock.

Which institutional investors are buying Equillium stock?

Within the last quarter, EQ stock was acquired by institutional investors including:
  1. Janus Henderson Group PLC
  2. Aberdeen Group plc
  3. Hudson Bay Capital Management LP
  4. Cantor Fitzgerald L. P.
  5. Renaissance Technologies LLC
  6. Royal Bank of Canada
  7. Balyasny Asset Management L.P.
  8. ADAR1 Capital Management LLC